S5127Referred to Committee
Harley Jacobsen Clinical Trial Participant Income Exemption Act of 2026
Introduced
In Committee
3
Passed One Chamber4
Passed Both5
Signed into Law119th
Congress
2026-07-23
Introduced
1
Cosponsors
S
ⓘType
Sponsor
Jim Banks
Republican · IN · Senator
Votes with party: 76.2% (866 recorded votes)
Full profile: /officials/B001299
Source: Congress.gov · FEC
Cosponsors (1)
Members who have signed on to support this bill since introduction. Source: Congress.gov.
Latest Action
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Committee Activity
Currently in
- Senate Committee on FinanceReferred To · 2026-07-23
Plain-English Summary
People who participate in medical research studies would not have to pay income taxes on the money they receive as compensation for their participation. This change would apply to clinical trial payments, making it easier for individuals to volunteer for medical research without worrying about tax consequences on those earnings. The change affects both the participants who volunteer for studies and the medical research companies or institutions that conduct the trials.
AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.
Full Bill Text
Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.
[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 5127 Introduced in Senate (IS)] <DOC> 119th CONGRESS 2d Session S. 5127 To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES July 23, 2026 Mr. Banks (for himself and Ms. Cortez Masto) introduced the following bill; which was read twice and referred to the Committee on Finance _______________________________________________________________________ A BILL To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Harley Jacobsen Clinical Trial Participant Income Exemption Act of 2026''. SEC. 2. EXCLUSION OF COMPENSATION PROVIDED TO PARTICIPANTS IN CLINICAL TRIALS. (a) In General.--Part III of subchapter B of chapter 1 of the Internal Revenue Code of 1986 is amended by inserting after section 139L the following new section: ``SEC. 139M. CLINICAL TRIAL PAYMENTS. ``(a) In General.--Gross income shall not include any amount received by an individual as a qualified clinical trial payment. ``(b) Qualified Clinical Trial Payment Defined.--For purposes of this section, the term `qualified clinical trial payment' means any amount paid to an individual-- ``(1) as compensation for participation by the individual or a dependent of the individual in an approved clinical trial, or ``(2) to reimburse or pay reasonable and necessary expenses incurred in connection with participation by the individual or a dependent of the individual in an approved clinical trial. ``(c) Other Definitions.--For purposes of this section-- ``(1) Approved clinical trial.--The term `approved clinical trial' has the meaning given such term in section 2709(d)(1) of the Public Health Service Act (42 U.S.C. 300gg-8(d)(1)), determined by substituting `disease or condition' for `life- threatening disease or condition'. ``(2) Dependent.--The term `dependent' has the meaning given such term in section 152.''. (b) Clerical Amendment.--The table of sections for part III of subchapter B of chapter 1 of such Code is amended by inserting after the item relating to section 139L the following new item: ``Sec. 139M. Clinical trial payments.''. (c) Effective Date.--The amendments made by this section shall apply to amounts paid after December 31, 2025. SEC. 3. CLINICAL TRIAL COMPENSATION NOT TAKEN INTO ACCOUNT FOR PURPOSES OF DETERMINING ELIGIBILITY FOR FEDERAL PROGRAMS OR ASSISTANCE. (a) In General.--Notwithstanding any other provision of law, any amount received by an individual as a qualified clinical trial payment shall not be taken into account as income or resources for purposes of determining the eligibility of such individual (or any other individual) for benefits or assistance (or the amount or extent of benefits or assistance) under any Federal program or under any State or local program financed in whole or in part with Federal funds. (b) Qualified Clinical Trial Payment.--For purposes of subsection (a), the term ``qualified clinical trial payment'' has the meaning given such term in section 139M(b) of the Internal Revenue Code of 1986 (as added by section 2 of this Act). <all>
Related legislation
Bills by the same sponsor or covering overlapping subjects.
- S3589RISE ActReferred to Committee · 2026-07-30
- S5172A bill to amend titles XI, XIX, and XXI of the Social Security Act with respect to screening for childhood-onset fluency disorders, and to require coverage of certain speech therapy services under Medicaid and CHIP.Referred to Committee · 2026-07-29
- S3794SAFE Drugs Act of 2026Reported by Committee · 2026-07-27
- S4954Citizenship Act of 2026Referred to Committee · 2026-07-13